Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

Part of paid clinical trials in Charleston, South Carolina.

Sponsor
Medical University of South Carolina
Study ID
NCT07720167
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Cemiplimab — DRUG
    administered at a dose of 350 mg as an intravenous infusion over 30 minutes
  • Carboplatin + Pemetrexed/Paclitaxel — DRUG
    every 21 days for three cycles if not using cisplatin
  • Cisplatin — DRUG
    every 21 days for three cycles if not using carboplatin and pemetrexed/paclitaxel

Study Details

The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of survival with surgery alone. Here will be examined the ability of 3 cycles of cemiplimab-chemotherapy to induce pathologic complete responses to treatment.

Key Dates

First listed
Jul 22, 2026
Start date
Nov 1, 2026
Status verified
Jul 2026
Primary completion
Nov 1, 2029
Completion
Nov 1, 2030

Study Design

Enrollment
38 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemiplimab+Investigator's choice platinum doublet for clinical stage 1, 2-3.9cm, NSCLC
    Patients will receive carboplatin + pemetrexed/paclitaxel or cisplatin. Followed by surgery. Safety labs and physical exam 3 weeks post-surgery. Long-term follow up.

Primary Outcome Measure

Frequency and percentage of patients with a pathologic complete response (pCR) rate [ Time Frame: 5.5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Medical University of South Carolina Hollings Cancer CenterCharlestonSouth Carolina29425
HCC Clinical Trials Office
[email protected]
843-792-9321

Find similar trials in Charleston, SC

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Medical University of South Carolina Hollings Cancer Center· Charleston, SC

Related Studies